Association between ovarian hormones and smoking behavior in women. by Schiller, Crystal Edler et al.
The Association Between Ovarian Hormones and Smoking
Behavior in Women
Crystal Edler Schiller, Ph.D.1,*, Michael E. Saladin, Ph.D.2,3, Kevin M. Gray, M.D.2, Karen J.
Hartwell, M.D.2, and Matthew J. Carpenter, Ph.D2
1Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC
2Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina,
Charleston, SC
3Department of Rehabilitation Sciences, Medical University of South Carolina, Charleston, SC
Abstract
Studies examining the association between menstrual cycle phases and smoking behavior in
women have yielded mixed results. The purpose of this study was to elucidate the associations
between ovarian hormones and smoking by directly measuring ovarian hormone levels and
obtaining a laboratory assessment of smoking behaviors. Four hypotheses were tested: increased
smoking will be associated with 1) low absolute levels of estradiol and progesterone; 2)
decreasing (i.e., dynamic changes in) estradiol and progesterone; 3) lower ratios of progesterone to
estradiol, and 4) higher ratios of estradiol to progesterone. Female smokers (≥10 cigarettes/day)
with regular menstrual cycles were recruited as part of a larger, ongoing study examining the
influence of ovarian hormones on smoking cessation treatment. Participants completed two study
visits, including a one-hour adlib smoking topography session, which provided a detailed
assessment of smoking behavior. Both the change in hormone levels over time and the relative
ratios of ovarian hormones were associated with smoking behavior, but each to a limited extent.
Decreases in estradiol (r=−.21, p=.048), and decreases in progesterone (r=−.23, p=.03) were
associated with increased puff intensity. Lower ratios of progesterone to estradiol were associated
with a greater number of puffs (r=−.26, p=.01) and weight of cigarettes smoked (r=−.29, p=.005).
The best predictors of smoking behavior were the ratio of progesterone to estradiol (z=−2.7, p=.
004) and the change in estradiol and progesterone over time (z=−2.1, p=.02). This pattern of
results may help to explain inconsistent findings in previous studies and suggest potential
mechanisms by which hormones influence nicotine addiction.
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Smoking is the leading cause of preventable death in the United States (Danaei et al., 2009).
Although men are more likely to smoke than women (USDHS, 2010), women may be more
sensitive to certain aspects of nicotine addition. For example, women are more sensitive to
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the subjective effects of nicotine (Myers, Taylor, Moolchan, & Heishman, 2008; Sofuoglu,
Mitchell, & Mooney, 2009) and more likely to cite tension reduction, stimulation, social
dynamics (Berlin et al., 2003), and appetite suppression as reasons for smoking (Reid, Pipe,
Riley, & Sorensen, 2009). Smoking is associated with significant health risks in women
(Perkins, 2001), and more women than men report having tried nicotine replacement therapy
(NRT) to quit smoking (Reid, et al., 2009). However, women are less likely than men to
achieve sustained abstinence following NRT (Bohadana, Nilsson, Rasmussen, & Martinet,
2003; Japuntich et al., 2011; Perkins, 2001).
Ovarian hormones may contribute to gender differences in nicotine addiction. Estradiol is
thought to enhance women’s sensitivity to nicotine, whereas progesterone is thought to be
protective (Lynch & Sofuoglu, 2010). Tonic progesterone administration in the context of
relatively low estradiol levels increases the subjective negative effects of nicotine, decreases
the subjective positive effects of nicotine, and reduces the urge to smoke in women
(Sofuoglu & Mooney, 2009). These findings are supported by experimental animal studies,
which have demonstrated decreased motivation for nicotine when progesterone levels are
high (Lynch, 2009). However, the effects of progesterone on smoking behavior in women
are less clear (Sofuoglu, Babb, & Hatsukami, 2001; Sofuoglu, Mouratidis, & Mooney,
2011).
The majority of research examining the effects of ovarian hormones on smoking has used
menstrual cycle phase as a proxy for ovarian hormone function. These studies typically
compare women in different phases of the menstrual cycle (e.g., follicular vs. luteal), and the
results have been quite mixed. Some studies show increased smoking during menses
(DeBon, Klesges, & Klesges, 1995; Marks, Hair, Klock, Ginsburg, & Pomerleau, 1994),
others show increased smoking during the late-luteal phase (DeBon, et al., 1995; Snively,
Ahijevych, Bernhard, & Wewers, 2000), and others show no relationship between cigarette
smoking and menstrual phase (Allen, Hatsukami, Christianson, & Nelson, 1996; Allen,
Hatsukami, Christianson, & Nelson, 1999; Pomerleau, Cole, Lumley, Marks, & Pomerleau,
1994).
Certain methodological issues may have contributed to the inconsistent findings across
studies. Previous studies used arbitrary phase classifications to denote differences in
hormonal milieu. Comparisons of one phase vs. another (follicular vs. luteal) can be
problematic to the extent that such phases are imperfect proxies of actual hormone levels
because estradiol and progesterone levels fluctuate significantly within cycle phases (see
Figure 1). Thus, the low absolute levels of estradiol and progesterone experienced during
menses {DeBon, 1995 #116}{Marks, 1994 #149}, the decreasing levels of estradiol and
progesterone experienced during the luteal-phase {DeBon, 1995 #116}{Snively, 2000
#113}, or the relative ratio of estradiol to progesterone (or vice versa) may be associated
with increased smoking. The ratios of ovarian hormones (estradiol/progesterone or
progesterone/estradiol) are associated with the exacerbation of a number of neurological and
psychiatric conditions, including the frequency of seizures in women with epilepsy (Herzog,
1999), the number and volume of brain lesions associated with multiple sclerosis (Pozzilli et
al., 1999), and menstrual distress in women with migraines (Beckham et al., 1992). Previous
studies of smoking cessation have used the ratio of estradiol to progesterone rather than the
reverse (Allen, Bade, Center, Finstad, & Hatsukami, 2008). Given that the two ratios (i.e.,
estradiol/progesterone and progesterone/estradiol) are not equivalent or linearly related,
either or both ratios may be of importance. Thus, a more rigorous examination of hormonal
influences on smoking behavior would focus on absolute and changing levels of both
progesterone and estradiol, and the relationship between hormones (i.e., the ratio of
progesterone to estradiol or vice versa).
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A second methodological issue that may have contributed to previous discrepant findings is
related to the assessment of smoking behaviors. Many previous studies have relied on self-
reported smoking behavior occurring hours or days following the assessment of menstrual
cycle phase or hormone levels, and this varying lag in time between predictor and outcome
likely accounts for different conclusions. It is critical that assessments, hormones and
smoking behaviors are temporally congruent in order to detect meaningful associations.
Thus, laboratory assessment is advantageous because smoking behaviors can be examined in
relation to hormones measured at the same time.
The current study examines data from an ongoing smoking cessation trial to elucidate the
relationship between ovarian hormones and smoking by directly measuring ovarian hormone
levels and obtaining a detailed laboratory assessment of smoking behaviors. While it is
difficult to derive a single, definitive hypothesis from the inconsistent findings noted above,
we tentatively propose the following four hypotheses: increased smoking will be associated
with 1) low levels of estradiol and progesterone; 2) decreasing estradiol and decreasing




Treatment-seeking female smokers (≥10 cigarettes/day) ages 18–45 years, having regular
menstrual cycles between 25 and 35 days and not taking hormonal contraceptives or
replacement were recruited from the community as part of a larger, ongoing study
examining the influence of ovarian hormones on smoking cessation treatment. Participants
were allowed to enter the study at any time during their menstrual cycle phase. Exclusion
criteria were current unstable major psychiatric or medical disorders, current substance use
disorders, and pregnancy or breastfeeding within the last three months. Women with
premenstrual symptoms were not excluded from participating in this study.
Procedures
The Medical University of South Carolina Institutional Review Board approved this study.
Participants were recruited from the community through local media advertising for a
smoking cessation study. At the first study visit (T1), participants provided written informed
consent and completed self-report questionnaires, including a demographic questionnaire
and the Fagerström Test for Nicotine Dependence (FTND; Heatherton et al., 1991). FTND
scores range from zero to 10, with higher scores indicating a greater degree of dependence.
Psychiatric interview using the Mini International Neuropsychiatric Interview (MINI;
Sheehan et al., 1998) was conducted to assess for exclusionary Axis I psychiatric diagnoses.
Five milliliters of blood were collected in order to conduct estradiol and progesterone
assays.
The second study visit (T2) was conducted approximately one to two weeks later (M=10.8
days, SD=8.0). Participants were instructed to abstain from smoking for 12 hours prior to
attending the second study visit, which was verified via carbon monoxide (CO) breathalyzer.
Women CO levels higher than 10ppm (n=5) were excluded from this study. A blood draw
was performed to allow determination of serum estradiol and progesterone levels.
Participants completed a one-hour ad libitum smoking topography session following a cue
reactivity session described elsewhere (see Saladin et al., in submission). Importantly, both
study visits and all data included in the current analyses occurred prior to the beginning of
the smoking cessation treatment phase. As such, none of the women were receiving
treatment.
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At the beginning of T2, the participant’s CO level was measured and her entire supply of
cigarettes was weighed. The participant was provided with an ashtray and permitted to
smoke her preferred brand of cigarettes, indoors ad libitum for 60 minutes using smoking
topography equipment (CReSSmicro System, Borgwadlt KC, Inc). During this time, the
participant had access to reading material provided by study personnel and was told to
deposit all cigarette butts in the ashtray provided by study personnel. At the end of the 60
minute period, the participant’s CO level was measured again to calculate the absolute
change in CO during the session. The number of cigarette butts was counted and the smoked
and unsmoked cigarettes were weighed.
The smoking topography device measured and recorded various aspects of the participant’s
smoking behavior, including number of puffs on the first cigarette and all cigarettes, total
number of cigarettes smoked, mean puff volume (mL) for the first cigarette and all
cigarettes, total puff volume (mL) for the first cigarette and all cigarettes, mean puff
duration (seconds) for the first cigarette and all cigarettes, mean flow rate (mL/second) for
the first cigarette and all cigarettes, and peak flow rate (mL/second) for the first cigarette
and all cigarettes. Flow rate represents the rate at which a volume of air is pulled in through
the smoking topography device and has been shown to affect CO delivery independently of
puff volume or duration (Robinson & Forbes, 1975).
Ovarian Hormone Measurement
Hormone assays were performed at the MUSC Clinical Core Laboratory using
chemilluminescent immunoassay. The unit of measurement was pg/mL for estradiol and ng/
mL for progesterone. Three separate ovarian hormone measurements served as independent
variables: 1) absolute hormone levels; 2) the absolute change in hormone levels between
study visits: and 3) the relative ratios of progesterone and estradiol. Absolute hormone levels
reflect estradiol and progesterone levels assessed at T2. The hormone change index
represents the absolute change in hormone levels between T1 and T2 (i.e., hormone change
= T2 estradiol level – T1 estradiol level). The ratio of progesterone to estradiol represents
the level of progesterone at T2 divided by the level of estradiol at T2. The ratio of
progesterone to estradiol is highest during the luteal phase and lowest during the follicular
phase of the menstrual cycle. Several studies examining the association between hormones
and craving have used the opposite ratio: estradiol divided by progesterone, and since the
E:P ratio is not linearly equivalent to the P:E ratio, we included both.
Statistical Analyses and Data Reduction
The smoking topography variables were subjected to data reduction techniques, including
factor analysis, in order to identify broader, underlying behavioral constructs. The rationale
for using factor analysis was threefold. First, the smoking topography device yielded a large
number of behavioral outcome measures, many of which were highly correlated. Analyzing
all of the outcomes separately would have required a large number of statistical tests, which
would have increased the family wise error rate. Moreover, running several analyses with
essentially the same dependent variable would have provided little incremental validity.
Second, data reduction would yield a more comprehensive representation of the underlying
behavioral constructs; this would be preferable to simply choosing a reduced set of variables
based on a theoretical-rational approach (Clark & Watson, 1995). Third, reducing the
variables to more robust constructs may have enhanced power and improved the likelihood
of finding meaningful associations with the ovarian hormone measures.
As a preliminary step, bivariate correlations between topography variables were examined.
When two variables were highly correlated (r > 0.80), one of the variables was eliminated.
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Determination of which variable to retain when two were correlated was based on the
strength of their associations with the remaining variables. Remaining variables were
subjected to a principal components analysis with varimax rotation. Estimated factor score
coefficients were used to create standardized composite variables, which have a mean of
zero and a standard deviation of one.
Of the 13 topography variables measured, five were eliminated to reduce redundancy in the
item pool. The remaining eight variables were subjected to a principal components analysis.
One variable, total puff volume, loaded highly on both factors 2 and 3, and was therefore
eliminated from the item pool. As shown in Table 1, the final principal components analysis
with varimax rotation yielded a three-factor solution. The three factors and the resulting
standardized variables were labeled “number of puffs,” “flow rate,” and “puff intensity,”
respectively.
Partial correlations were used to examine associations between ovarian hormone measures
and the smoking variables, controlling for age and FTND scores because both age and
FTND were significantly associated with the smoking variables (p’s<.05). The hormone
variables included: 1) absolute hormone levels at T2; 2) the ratio of progesterone to estradiol
(P:E) and the ratio of estradiol to progesterone (E:P); and 3) the change in hormone levels
between study visits T1 and T2 (as outlined in section 2.5). In order to examine which
hormone variable best predicts smoking behavior, the difference between effect sizes was
directly tested using methods described by Meng, Rosenthal, & Rubin (1992). In addition,
hierarchical linear regression analyses were used to determine the amount of variance in
smoking behavior accounted for by ovarian hormones. Age and FTND were entered into the
first block, and the ovarian hormone variable of interest was entered into the second block.
Results
Participant Characteristics
On average, participants (N=98) were 31.2 (SD=7.6) years old. Almost all (97%) were non-
Hispanic, and the racial composition of the participants was 79% White, 16% African-
American, 2% Native Hawaiian or Pacific Islander, and 3% other. Most participants had
completed high school (60%), and an additional 32% had completed college. The average
FTND score was 4.8 (SD=2.3). The mean (SD) estradiol level was 128.5 pg/mL (72.7) at T1
and 95.9 pg/mL (69.9) at T2. The mean (SD) progesterone level was 6.4 ng/mL (7.1) at T1
and 4.7 ng/mL (6.2) at T2. Reference ranges adapted for the Siemens Advia Centaur
Immunoassay System used in this study suggest that progesterone levels less than 1.5 ng/mL
are indicative of the follicular phase in premenopausal women, whereas levels greater than
1.6 ng/mL are indicative of the luteal phase. Based on these ranges, we estimate that at T1,
63% of participants were in the luteal phase and 37% were in the follicular phase; and at T2,
51% were in the luteal phase and 49% were in the follicular phase.
Ovarian Hormones and Smoking Behaviors
Average values of the smoking topography measures prior to standardization are shown in
Table 1. Partial correlations between the hormone variables, the three standardized smoking
topography composite variables, and the boost in CO levels, controlling for age and FTND,
are shown in Figure 2. The boost in CO levels during the topography session was not
significantly associated with any of the hormone variables and is not included in the figure.
In addition, absolute levels of estradiol and progesterone were not significantly associated
with any of the smoking variables.
Partial correlations between the ratio of progesterone to estradiol and each of the smoking
variables, controlling for age and FTND, are shown in Figure 2. The ratio of progesterone to
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estradiol was negatively correlated with the number of puffs variable (r=−.26, p=.01) and the
weight of cigarettes smoked (r=−.29, p=.005). Thus, participants with lower levels of
progesterone relative to estradiol took more puffs during the topography session and smoked
a greater mass of cigarettes. Hierarchical linear regression demonstrated that the ratio of
progesterone to estradiol accounted for 5% of the variance in the weight of cigarettes
smoked and 6% of the variance in the number of puffs. In contrast, the ratio of estradiol to
progesterone was not significantly correlated with any of the smoking variables.
Correlations between the hormone change indexes and each of the smoking variables are
also shown in Figure 2. There was a significant negative association between puff intensity
and absolute changes in both estradiol (r=−.21, p=.048) and progesterone (r=−.23, p=.03).
Thus, during the time between T1 and study T2, larger decreases in estradiol and
progesterone were associated with greater puff intensities during the adlib smoking session.
Hierarchical linear regression demonstrated that the change in estradiol and progesterone
each accounted for 4% and 5% of the variance in puff intensity, respectively.
Compared to the other hormone variables, the ratio of progesterone to estradiol was the best
predictor of the number of puffs (z=−2.3, p=.01) and weight of cigarettes smoked (z=−2.7,
p=.004) during the topography session. The estradiol and progesterone change indexes were
the best predictors of puff intensity (z=−2.1, p=.02).
Discussion
This study aimed to elucidate the relations between ovarian hormones and smoking
behavior. Our study is strengthened by the direct and multivariate assessment of hormone
levels at a time when they were temporally congruent with the assessment of smoking
behavior, which was also defined in multiple ways. Topography variables were reduced to
three meaningful factors: number of puffs, flow rate, and puff intensity. The three factors
appear to assess different aspects of smoking behavior, and they were differentially related
to the ovarian hormone variables assessed.
The results of this study suggest that both the change in hormone levels over time and the
relative ratio of progesterone to estradiol appear to influence smoking behavior, but each to
a limited extent. Our results may help to explain inconsistent findings in previous studies
and suggest potential mechanisms by which hormones influence nicotine addiction.
Decreasing estradiol and decreasing progesterone were also associated with greater puff
intensities in the current study. These results are consistent with a previous study by Snively
and colleagues that found increased smoking during the late luteal phase (Snively, et al.,
2000), which is characterized by both decreasing estradiol and progesterone.
Although variance in smoking behaviors accounted for by ovarian hormone measures seen
in this study was small (4–6%), gender differences in nicotine dependence and ovarian
hormone function remain an important area of investigation. According to Cohen (1992), r=.
10 represents a small effect size, whereas .3 and .5 represent medium and large effect sizes,
respectively. Rosenthal (1990) has asserted that even small associations between variables
are often meaningful in a practical context. Examples include the “small” associations
between smoking and mortality, aspirin use and myocardial infarction, and gender and
chronic heart disease (Rutledge & Loh, 2004).
Consistent with the notion that estradiol may increase sensitivity to nicotine, whereas
progesterone is protective (Lynch & Sofuoglu, 2010), high levels of progesterone relative to
estradiol (i.e., P:E ratio) were associated with a lower number of puffs and a smaller mass of
cigarettes smoked. Conversely, low levels of progesterone relative to estradiol were
associated with a higher number of puffs and a greater mass of cigarettes smoked. Notably,
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this effect cannot be explained by the effect of progesterone alone on smoking because the
absolute level of progesterone was not significantly associated with smoking. Instead,
progesterone appears to reduce smoking behavior only when it is not opposed by estradiol.
These findings are consistent with animal and human studies demonstrating diminished
interest in nicotine following progesterone administration in the context of low levels of
estradiol (Lynch, 2009; Sofuoglu & Mooney, 2009) and diminished relapse rates among
female smokers who quit during the luteal phase compared to the follicular phase (Allen, et
al., 2008). In this study, the P:E ratio was more strongly correlated with smoking behavior
than the E:P ratio, which suggests that the level of progesterone relative to estradiol rather
than the reverse should be examined in future studies of smoking behavior.
Results of this study suggest that the best predictors of smoking behavior are the ratio of
progesterone to estradiol and the change in ovarian hormones over time. However, the
mechanism by which decreasing ovarian hormones influence the volume and duration of
cigarette puffs is unclear, as is how a low ratio of progesterone to estradiol influences
smoking behavior. Future studies should replicate these findings and explore potential
mechanisms by which changes in hormone levels and the ratio of progesterone to estradiol
differentially influence smoking behavior.
In the current study, the smoking measures were collected during an adlib smoking session
without any alternative reinforcers. The addition of an alternative reinforcer to smoking
(e.g., money) may increase the effect size of steroid hormones on smoking behavior in
future studies. Moreover, ovarian hormones may affect smoking behaviors in some women
more than others, which could explain the small effect sizes detected in the current study.
For example, it is well established that some women are differentially sensitive to the effects
of ovarian hormones (Rubinow, Schmidt, & Roca, 1998). Moreover, previous research
suggests an increased desire to smoke and to relieve negative affect during the late luteal
phase only among women with premenstrual symptoms (Allen, et al., 1999). The effects of
hormones on smoking may therefore be greater in women who experience premenstrual
symptoms. Future studies may identify subpopulations of female smokers acutely sensitive
to the effects of ovarian hormones.
This study had certain weaknesses. First, the controlled laboratory environment in which the
study was conducted and the inclusion of treatment-seeking women limits the
generalizability of the results. Second, estradiol and progesterone were measured relatively
infrequently. The hormone change indexes created in this study represent the change in
hormone levels between the first and second study visits, which were approximately 11 days
apart. Hormones change significantly over the course of 11 days in normally cycling
women, and thus, the hormone change index was a very rough indicator of change over
time. More refined (e.g., daily) hormonal assessment is preferred, but feasibility may be
diminished. Recent advances in hormone assay techniques allow for ovarian hormone
detection in saliva rather than plasma. Salivary sampling methods are not only easier and
more acceptable to women, but they also detect the unbound or “biologically available”
portion of ovarian hormones, allowing for more powerful analyses of associations between
hormones and behavioral symptoms (Edler, Lipson, & Keel, 2007; Shirtcliff et al., 2000).
Fourth, the effects of the cue reactivity assessment that immediately preceded the adlib
smoking procedure are unknown. However, all subjects received the same cue reactivity
procedure, regardless of menstrual phase, and thus, it is unlikely that the cue reactivity
session had a meaningful effect on the associations between hormones and smoking. Finally,
a more direct test of the hypothesis that ovarian hormones influence smoking behavior in
women could come from future experimental studies wherein exogenous estradiol and
progesterone are administered to female smokers and the subsequent effects on smoking are
examined. Future studies could also examine whether nicotine consumption per se or
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smoking behavior more generally are affected by changing hormone levels by examining
differences in behavior when subjects are given denicotinized versus regular nicotine-
containing cigarettes.
Advances in this line of research may lead to novel pharmacological treatments for nicotine
dependence. For example, women who are less likely to achieve abstinence may benefit
from a combination treatment such as varenicline plus transdermal progesterone.
Alternatively, reducing the cyclic fluctuations in ovarian hormones with hormonal
contraceptives may attenuate the exacerbation of smoking behavior seen in the late luteal
phase. An improved understanding of the association between ovarian hormone levels and
smoking could be used to enhance behavioral smoking interventions. By helping women to
identify predictable biological triggers for smoking, behavioral strategies could be
implemented to prepare women for periods of increased urges to smoke.
In conclusion, the ratio of progesterone to estradiol and the change in hormone levels over
time were the strongest hormonal predictors of smoking behavior. Ovarian hormone
function remains a primary candidate for explaining gender differences in nicotine
addiction. Future studies are needed to elucidate the neurobiological mechanisms by which
hormones influence smoking and to determine the utility of ovarian hormone manipulation
in augmenting women’s response to smoking cessation treatment.
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Approximate ovarian hormone levels during the menstrual cycle.
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Correlations between ovarian hormone measures and smoking behaviors. E = estradiol. P =
progesterone. Absolute P Level = absolute level at T2. Absolute E level = absolute level at
T2. P:E Ratio = ratio of progesterone to estradiol at T2. E:P Ratio = ratio of estradiol to
progesterone at T2. E Change = absolute change in estradiol level between T1 and T2. P
Change = absolute change in progesterone between T1 and T2.
*p<.05, **p<.01.
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